Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7600 (-2.32%) ($10.7600 - $10.7600) on Tue. Nov. 21, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.35% (three month average) | RSI | 49 | Latest Price | $10.7600(-2.32%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD declines -2.3% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) SMH(93%) IVW(80%) QQQ(74%) SPY(74%) XBI(73%) | Factors Impacting FOLD price | FOLD will decline at least -1.675% in a week (0% probabilities). TBT(-23%) UUP(-20%) UNG(-4%) URA(-3%) VIXM(4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.675% (StdDev 3.35%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $10.87 | 5 Day Moving Average | $10.77(-0.09%) | 10 Day Moving Average | $10.67(0.84%) | 20 Day Moving Average | $10.87(-1.01%) | To recent high | -19.4% | To recent low | 8% | Market Cap | $2.778b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |